Loading
Blood and tissue samples collected in cancer trials are the best material for validating new tests, but most sit unused under contracts that make access impossible. A commons would make them available for approved research.
Sponsors and academic trial groups deposit or catalogue residual biospecimens from completed trials (with linked clinical outcomes) in a federated commons with a single access committee, standard consent language for future trials that permits secondary research, and cost-recovery pricing. Access priority goes to biomarker validation studies and to negative-trial samples that can explain why drugs failed. The NCI's cooperative group banks and the EORTC's SPECTA show the model at small scale; the change is universal deposit obligations and one door to knock on.
Shares Proteomics & phosphoproteomics, Companion diagnostics, Liquid biopsy (ctDNA).
Shares Proteomics & phosphoproteomics, Biomarkers are not validated or standardised, Liquid biopsy (ctDNA).
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
Shares Proteomics & phosphoproteomics, Liquid biopsy (ctDNA).
Shares Proteomics & phosphoproteomics, Biomarkers are not validated or standardised, Liquid biopsy (ctDNA).
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
Shares Proteomics & phosphoproteomics, Companion diagnostics.
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.